NASDAQ:ABIO

ARCA biopharma (ABIO) Stock Price, News & Analysis

$3.50
-0.13 (-3.58%)
(As of 01:28 PM ET)
Today's Range
$3.41
$3.66
50-Day Range
$1.63
$3.65
52-Week Range
$1.56
$3.88
Volume
48,031 shs
Average Volume
1.13 million shs
Market Capitalization
$50.75 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ABIO stock logo

About ARCA biopharma Stock (NASDAQ:ABIO)

ARCA biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with heart failure. It is developing Recombinant Nematode Anticoagulant Protein c2, a protein therapeutic that is in Phase IIb clinical trial for the treatment for COVID-19. The company has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.

ABIO Stock Price History

ABIO Stock News Headlines

ARCA biopharma Inc
Mysterious Gold Leverage Just Announced
World's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.
StockNews.com Begins Coverage on ARCA biopharma (NASDAQ:ABIO)
Why Is ARCA Biopharma (ABIO) Stock Up 85% Today?
Mysterious Gold Leverage Just Announced
World's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.
ABIO Apr 2024 2.500 call
See More Headlines
Receive ABIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ARCA biopharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/01/2024
Today
4/25/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Diagnostic substances
Sub-Industry
N/A
Current Symbol
NASDAQ:ABIO
Employees
4
Year Founded
N/A

Profitability

Net Income
$-5,340,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.89 per share

Miscellaneous

Free Float
10,020,000
Market Cap
$52.64 million
Optionable
Optionable
Beta
1.17
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Dr. Michael R. Bristow M.D. (Age 79)
    Ph.D., Co-Founder, President, CEO & Director
    Comp: $358.8k
  • Mr. C. Jeffrey Dekker CPA (Age 59)
    CFO, Treasurer & Company Secretary
    Comp: $323.07k
  • Mr. Thomas A. Keuer (Age 65)
    Chief Operating Officer
    Comp: $400.8k

ABIO Stock Analysis - Frequently Asked Questions

How have ABIO shares performed in 2024?

ARCA biopharma's stock was trading at $1.70 at the beginning of the year. Since then, ABIO stock has increased by 105.9% and is now trading at $3.50.
View the best growth stocks for 2024 here
.

Are investors shorting ARCA biopharma?

ARCA biopharma saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 5,660,000 shares, an increase of 2,792.2% from the March 31st total of 195,700 shares. Based on an average daily trading volume, of 1,380,000 shares, the short-interest ratio is presently 4.1 days. Approximately 39.6% of the shares of the company are sold short.
View ARCA biopharma's Short Interest
.

When is ARCA biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, April 29th 2024.
View our ABIO earnings forecast
.

How were ARCA biopharma's earnings last quarter?

ARCA biopharma, Inc. (NASDAQ:ABIO) announced its quarterly earnings data on Thursday, February, 1st. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter.

What is Michael R. Bristow's approval rating as ARCA biopharma's CEO?

1 employees have rated ARCA biopharma Chief Executive Officer Michael R. Bristow on Glassdoor.com. Michael R. Bristow has an approval rating of 100% among the company's employees. This puts Michael R. Bristow in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of ARCA biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ARCA biopharma investors own include Aurora Cannabis (ACBFF), MannKind (MNKD), Bausch Health Companies (BHC), Biocept (BIOC), Novavax (NVAX), AVEO Pharmaceuticals (AVEO), Gilead Sciences (GILD), iBio (IBIO), Nabriva Therapeutics (NBRV) and Synergy Pharmaceuticals (SGYP).

How do I buy shares of ARCA biopharma?

Shares of ABIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ABIO) was last updated on 4/25/2024 by MarketBeat.com Staff

From Our Partners